With PhI win, Prexton targets Phase IIPrexton Therapeutics is taking aim at Phase II: The Swiss company happily presented results for its Phase I trial of its mGluR4 positive allosteric modulator in Parkinsons Disease, saying the first-in-class … more ➔
Novozymes bags Organobalance Denmarks Novozymes has acquired microbial research company Organobalance GmbH. The German company owns a large collection of microbial strains, some of which date back to the 1920s, and has strong … more ➔
AC Immune boldly prices Nasdaq IPO14.09.2016 – The summer slump on the stock markets is over: AC Immune has confidently priced its long-awaited Nasdaq IPO. The Swiss Alzheimers specialist is expecting to raise up to US$68m (€60.5m) … more ➔
Sanofi, Google launch diabetes venture13.09.2016 – Diabetes major Sanofi is joining forces with Verily – formerly Google Life Sciences – to launch Onduo. The joint venture will develop a comprehensive diabetes management platform. more ➔
Fresh French fund for healthcare09.09.2016 – iBionexts healthcare VC fund iBionext Growth has announced a first closing of €46m. All in all, iBionext aims to take in around €100m to reinvest in biotech and medtech companies. … more ➔
Bed and board go bio-based07.09.2016 – Furniture giant Ikea and renewables expert Neste have joined forces to deliver bio-based plastics based on Neste’s bio-based polymer. The partners urge other companies to join the initiative. more ➔
Boosting vaccines without the prick06.09.2016 – DBVs needle-free patch technology is being put to the test in a a proof of concept trial for a pertussis vaccine developed by BioNet-Asia. Researchers from the Geneva University Hospital … more ➔
Biomarker lifts a secret of old age05.09.2016 – Why do people grow old? Italian researchers took a close look at centenarians and found that low levels of the peptide hormone Adrenomedullin may significantly contribute towards good microcirculation … more ➔
mAb ray of hope for Alzheimers01.09.2016 – The causes of Alzheimer’s disease are still largely unknown. But now, an antibody developed by the University of Zurich has significantly reduced the brain amyloid plaques typical for Alzheimers … more ➔
Ferring bags slipped disk pain drug30.08.2016 – Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagakus Phase III chemonucleolytic leg pain treatment for €85m. more ➔
